tirzepatide fda approval date Approves Tirzepatide, A Potential Blockbuster Drug for Type 2 Diabetes Tirzepatide Gets FDA Approval for

doi: 10.1212/CON.0000000000001103 [PubMed] 35449037 Bilbao-Meseguer I, Barrasa H, Rodrguez-Gascn A, Asn-Prieto E, Maynar J, Snchez-Izquierdo J, Solins M, Isla A

Weng CJ, Hsieh YH, Chen MK, Tsai CM, Lin CW, Yang SF

Quick Answer: Zepbound causes nausea and sickness in 24-30% of patients primarily by slowing gastric emptying, which delays food movement from the stomach and triggers gastrointestinal discomfort

Patients typically describe this as mild to moderate queasiness, often most noticeable within a few hours after eating

Patients often pay less than the retail price, contingent on insurance structures such as copay or coinsurance frameworks, and successful prior authorization

It's important to note that in the UK, weight management medications like Wegovy and Saxenda are typically initiated within specialist weight management services following NICE criteria